| ●Editorial | Kurihara M | 222-4 |
| ●Knowledge management and knowledge sharing | ||
| Knowledge management (KM) and public understanding of science (PUS) −The view from social epistemology on medicine and medical research− | 225-56 | |
| Special contribution: STS and Professor Fuller's visit to ICU | Murakami Y | 226-7 |
| Interview: Knowledge management (KM) and public understanding of science (PUS) | Fuller S, Kanamori O, et al. | 228-56 |
| Sensitizing capability - From knowledge management to knowledge creation | Nonaka I, Tsuyuki E | 257-73 |
| The Interaction ontology for drug functional knowledge base (Yoshikawa) | Yoshikawa S, Konagaya A | 275-86 |
| Beyond the walls of the pharmaceutical industry | Matsumoto K | 287-9 |
| Challenges for the standardization of data management−CDISC | Ichihara R | 291-3 |
| NIH is selling its research products at its "supermarket" −Then, the mission of "white night" | Ferguson SM | 295-301 |
| Britain's gift: a "Medline" of synthesized evidence: Worldwide free access to evidence-based resources could transform health care | Smith R, Chalmers I (tans. by Saio T) | 303-5 |
| ●Topics | ||
| Interview with Delon Human, Secretary General of the World Medical Association −Discussion on the 2000 revision to the Declaration of Helsinki and onwards | Human D | 307-13 |
| ●Present status and the future of quality assurance in clinical trials | ||
| The present situation and issues concerning good clinical practice (GCP) inspection in Japan | Nagai N | 315-27 |
| The present situation and issues concerning Good Clinical Practice (GCP) inspection in Japan−The results of GCP inspection, Apr.-Nov. 2001− | Onishi J | 329-32 |
| Present status of data management in clinical trials in the medical institution and its future directions | Ohashi K | 333-44 |
| Future directions based on a case study of GCP compliance inspections −A GCP auditor's view− | Takezawa M, et al. | 345-53 |
| Importance of the quality management system at investigational sites for clinical trials | Tanaka S | 355-60 |
| Pathology peer review as a means of quality assurance for toxicological pathology | Takahashi M | 361-6 |
| Relation between clinical trial's process and compliance review | Editorial Committee | 367 |
| Services concerning compliance review for new drugs of OSPR | Editorial Committee | 368-70 |
| ●Leading article | ||
| Clinical trial of antidepressants −Theory and practice− | Kurihara M | 371-89 |
| ●Forum | ||
| Is "evidence-based medicine" a new paradigm in medicine? | Yamamoto W | 391-2 |
| Clinical evaluation and children | Sakakibara Y | 392-5 |
| ●Instructions for authors [English] | 397-402 | |
| ●Editor's note | Ysubaki H | 403 |